|
A phase II clinical study evaluating the efficacy and safety of neoadjuvant and adjuvant sunitinib in previously untreated patients with metastatic renal cell carcinoma (mRCC)(NeoSun). |
| |
|
No Relationships to Disclose |
| |
|
Consulting or Advisory Role - Novartis; Pfizer; Roche |
Research Funding - AVEO; MSD; Pfizer; Roche |
Travel, Accommodations, Expenses - Bristol-Myers Squibb |
| |
|
|
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
Research Funding - GE Healthcare; GE Healthcare (I); GlaxoSmithKline (Inst) |
| |
|
Travel, Accommodations, Expenses - American Medical Systems |
| |
|
No Relationships to Disclose |
| |
Timothy George Quentin Eisen |
No Relationships to Disclose |